The significant debt issuance combined with substantial equity dilution from the concurrent stock offering creates substantial overhang on the stock. The 35% premium to current price for conversion is high, making conversion unlikely in the near term. The low interest rate suggests market confidence in the company's credit, but the structural subordination of the notes to subsidiary liabilities increases risk. Traders should watch for potential negative sentiment from the dual capital raise.
Price Chart
Executive Summary
Revolution Medicines is raising $500 million through a 0.50% convertible senior notes offering due 2033, with an additional concurrent $1.4 billion common stock offering. The notes offer a low interest rate and conversion into equity if the stock price exceeds 130% of the conversion price, but carry significant dilution risk and subordination in the capital structure.
Key Facts
- Company is offering $500 million in 0.50% convertible senior notes due 2033
- Concurrent common stock offering of $1.435 billion (up to $1.65 billion if option exercised)
- Initial conversion price of $198.80 per share, representing a 35% premium to current stock price of $147.01
- Notes are senior unsecured obligations, structurally subordinated to subsidiary liabilities
- Proceeds will be used for general corporate purposes including R&D and potential commercialization
Financial Impact
$500 million in new debt and up to $1.65 billion in equity dilution from concurrent offerings
Risk Factors
- Significant equity dilution from concurrent stock offering
- Structural subordination of notes to subsidiary liabilities
- Low likelihood of note conversion given 35% premium to current stock price
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-157268 |
| Document: d124966dexfilingfees.htm | 0001193125-26-157268 |
| Document: 0001193125-26-157268-index-headers.html | 0001193125-26-157268 |
| Document: 0001193125-26-157268-index.html | 0001193125-26-157268 |
| Document: 0001193125-26-157268.txt | 0001193125-26-157268 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Apr 17, 2026 24w ago | 8-K | $1.88 $9.07 | ▼ −382.45% | ▼ −375.67% | — |
Apr 16, 2026 24w ago | 8-K | $1.88 $8.98 | ▲ +377.66% | ▲ +371.52% | — |
Apr 15, 2026 24w ago | 424B5 | $1.88 $8.96 | ▲ +376.60% | ▲ +369.55% | — |
Apr 15, 2026 24w ago | 424B5 | $1.88 $8.96 | ▼ −376.60% | ▼ −369.55% | — |
Apr 15, 2026 24w ago | 144 | $1.88 $8.96 | ▼ −376.60% | ▼ −369.55% | — |
Apr 13, 2026 24w ago | 424B5 | $1.88 $9.82 | ▼ −422.13% | ▼ −413.61% | — |
Apr 13, 2026 24w ago | 424B5 | $1.88 $9.82 | ▼ −422.13% | ▼ −413.61% | — |
Apr 13, 2026 24w ago | 8-K | $1.88 $9.66 | ▲ +413.83% | ▲ +404.91% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access